{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Bailey HH"],"funding":["NCI NIH HHS"],"pagination":["285-290"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7910313"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["30(3)"],"pubmed_abstract":["Resveratrol (3,4,5-trihydroxystilbene) is a naturally occurring phytoalexin with purported health-promoting effects, but with limited oral bioavailability. Our prior murine modeling research observed enhanced resveratrol bioavailability with piperine co-administration. In this study, single-dose pharmacokinetics of resveratrol with or without piperine and the associated toxicities were studied on a cohort of healthy volunteers. We performed a double-blind, randomized, three-arm pilot study. Participants were randomized to receive a single dose of resveratrol 2.5 g, with piperine in 0 mg, 5 mg, or 25 mg dose. An improved liquid chromatography/mass spectrometry assay was used to determine serum levels of resveratrol and resveratrol-glucuronide. Baseline through 24 h post-study drug serum ana"],"journal":["European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)"],"pubmed_title":["A randomized, double-blind, dose-ranging, pilot trial of piperine with resveratrol on the effects on serum levels of resveratrol."],"pmcid":["PMC7910313"],"funding_grant_id":["R21 CA149560","P30 CA014520"],"pubmed_authors":["Scarlett CO","Johnson JJ","Lozar T","Wollmer BW","Kim K","Havinghurst T","Bailey HH","Ahmad N"],"additional_accession":[]},"is_claimable":false,"name":"A randomized, double-blind, dose-ranging, pilot trial of piperine with resveratrol on the effects on serum levels of resveratrol.","description":"Resveratrol (3,4,5-trihydroxystilbene) is a naturally occurring phytoalexin with purported health-promoting effects, but with limited oral bioavailability. Our prior murine modeling research observed enhanced resveratrol bioavailability with piperine co-administration. In this study, single-dose pharmacokinetics of resveratrol with or without piperine and the associated toxicities were studied on a cohort of healthy volunteers. We performed a double-blind, randomized, three-arm pilot study. Participants were randomized to receive a single dose of resveratrol 2.5 g, with piperine in 0 mg, 5 mg, or 25 mg dose. An improved liquid chromatography/mass spectrometry assay was used to determine serum levels of resveratrol and resveratrol-glucuronide. Baseline through 24 h post-study drug serum ana","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 May","modification":"2025-04-04T19:53:39.391Z","creation":"2025-04-04T19:53:39.391Z"},"accession":"S-EPMC7910313","cross_references":{"pubmed":["32868637"],"doi":["10.1097/cej.0000000000000621","10.1097/CEJ.0000000000000621"]}}